Deramciclane API Manufacturers

compare suppliers & get competitive offers

Pharmaoffer_donkere_achtergrond
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Deramciclane is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Deramciclane or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Deramciclane API 120444-71-5?

Description:
Here you will find a list of producers, manufacturers and distributors of Deramciclane. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Deramciclane 
Synonyms:
 
Cas Number:
120444-71-5 
DrugBank number:
DB06512 
Unique Ingredient Identifier:
O5KFK61E74

General Description:

Deramciclane, identified by CAS number 120444-71-5, is a notable compound with significant therapeutic applications. Deramciclane (EGIS-3886) is used for the treatment of a number of anxiety disorders. Deramciclane differs from other anti anxiety medications in that it is not a benzodiazepine and so has a different structure and target. It antagonizes 5-HT2A receptors, agonizes 5-HT2C receptors, and functions as a GABA reuptake inhibitor.

Indications:

This drug is primarily indicated for: Investigated for use/treatment in anxiety disorders. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Mechanism of Action:

Deramciclane functions by: Deramciclane is a new putative non-benzodiazepine-type anxiolytic compound. It is a selective serotonin 5-HT(2A) and 5-HT(2C) receptor antagonist and has also inverse agonist properties. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Classification:

Deramciclane belongs to the class of organic compounds known as bicyclic monoterpenoids. These are monoterpenoids containing exactly 2 rings, which are fused to each other, classified under the direct parent group Bicyclic monoterpenoids. This compound is a part of the Organic compounds, falling under the Lipids and lipid-like molecules superclass, and categorized within the Prenol lipids class, specifically within the Monoterpenoids subclass.

Categories:

Deramciclane is categorized under the following therapeutic classes: Anti-Anxiety Agents, Anticonvulsants, Antidepressive Agents, Bicyclic Monoterpenes, Bridged-Ring Compounds, Central Nervous System Agents, Central Nervous System Depressants, Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP2D6 Inhibitors (weak), Cytochrome P-450 Enzyme Inhibitors, Monoterpenes, Neurotransmitter Agents, Norbornanes, Psychotropic Drugs, Serotonin 5-HT2 Receptor Antagonists, Serotonin 5-HT2A Receptor Antagonists, Serotonin Agents, Serotonin Receptor Antagonists, Terpenes, Tranquilizing Agents. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Deramciclane is a type of Anti-anxiety


The Anti-anxiety category in the pharmaceutical API (Active Pharmaceutical Ingredient) market refers to a group of substances specifically developed to alleviate symptoms associated with anxiety disorders. Anxiety disorders are mental health conditions characterized by excessive worry, fear, and unease that can significantly impact daily life.

Pharmaceutical APIs within the Anti-anxiety category work by modulating the activity of neurotransmitters in the brain, particularly gamma-aminobutyric acid (GABA). GABA is an inhibitory neurotransmitter that helps regulate the excitability of neurons. By enhancing GABA's inhibitory effects, these APIs promote a calming effect, reducing anxiety symptoms.

Common Anti-anxiety APIs include benzodiazepines, such as alprazolam, diazepam, and lorazepam. These substances act as central nervous system depressants, inducing sedation and relaxation. Other APIs in this category include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and certain antihistamines.

Pharmaceutical companies develop and manufacture Anti-anxiety APIs to meet the growing demand for effective anxiety treatment options. These APIs are typically used as the active ingredient in the production of various anti-anxiety medications, such as tablets, capsules, or liquid formulations.

The market for Anti-anxiety APIs is influenced by factors such as increasing awareness about mental health, rising prevalence of anxiety disorders, and the growing demand for personalized treatment options. Regulatory compliance, quality control, and safety are crucial considerations in the development and production of these APIs to ensure efficacy and minimize potential side effects.

Overall, Anti-anxiety APIs play a vital role in the pharmaceutical industry by providing effective solutions for individuals struggling with anxiety disorders, enhancing their quality of life, and promoting overall well-being.